Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Epidemiol Infect ; 146(7): 920-930, 2018 05.
Article in English | MEDLINE | ID: mdl-29636119

ABSTRACT

Coinfection with human immunodeficiency virus (HIV) and viral hepatitis is associated with high morbidity and mortality in the absence of clinical management, making identification of these cases crucial. We examined characteristics of HIV and viral hepatitis coinfections by using surveillance data from 15 US states and two cities. Each jurisdiction used an automated deterministic matching method to link surveillance data for persons with reported acute and chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, to persons reported with HIV infection. Of the 504 398 persons living with diagnosed HIV infection at the end of 2014, 2.0% were coinfected with HBV and 6.7% were coinfected with HCV. Of the 269 884 persons ever reported with HBV, 5.2% were reported with HIV. Of the 1 093 050 persons ever reported with HCV, 4.3% were reported with HIV. A greater proportion of persons coinfected with HIV and HBV were males and blacks/African Americans, compared with those with HIV monoinfection. Persons who inject drugs represented a greater proportion of those coinfected with HIV and HCV, compared with those with HIV monoinfection. Matching HIV and viral hepatitis surveillance data highlights epidemiological characteristics of persons coinfected and can be used to routinely monitor health status and guide state and national public health interventions.


Subject(s)
Coinfection/epidemiology , HIV Infections/epidemiology , Hepatitis, Viral, Human/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Coinfection/virology , Female , HIV Infections/virology , Hepatitis, Viral, Human/virology , Humans , Infant , Infant, Newborn , Male , Middle Aged , Public Health , United States/epidemiology , Young Adult
2.
Clin Genet ; 91(4): 545-556, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27322592

ABSTRACT

Genomic risk information for potentially actionable complex diseases and pharmacogenomics communicated through genomic counseling (GC) may motivate physicians and patients to take preventive actions. The Ohio State University-Coriell Personalized Medicine Collaborative is a randomized trial to measure the effects of in-person GC on chronic disease patients provided with multiplex results. Nine personalized genomic risk reports were provided to patients through a web portal, and to physicians via electronic medical record (EMR). Active arm participants (98, 39% female) received GC within 1 month of report viewing; control arm subjects (101, 54% female) could access counseling 3-months post-report viewing. We examined whether GC affected documentation of physician-patient communication by reviewing the first clinical note following the patient's GC visit or report upload to the EMR. Multivariable logistic regression modeling estimated the independent effect of GC on physician-patient communication, as intention to treat (ITT) and per protocol (PP), adjusted for physician educational intervention. Counselees in the active arm had more physician-patient communications than control subjects [ITT, odds ratio (OR): 3.76 (95% confidence interval (CI): 1.38-10.22, p < 0.0094); PP, OR: 5.53 (95% CI: 2.20-13.90, p = 0.0017). In conclusion, GC appreciably affected physician-patient communication following receipt of potentially actionable genomic risk information.


Subject(s)
Cardiovascular Diseases/epidemiology , Electronic Health Records , Pharmacogenetics , Physician-Patient Relations , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/genetics , Cardiovascular Diseases/pathology , Communication , Female , Genetic Counseling , Genome, Human , Humans , Male , Middle Aged , Ohio , Physicians , Precision Medicine , Risk Assessment
3.
Clin Genet ; 85(1): 54-8, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23725378

ABSTRACT

Thousands of individuals have undergone mutational analysis of BRCA1 and BRCA2. The Ohio State University Clinical Cancer Genetics program has identified 466 individuals from 289 families with a mutation in BRCA1 or BRCA2. Excluding Ashkenazi Jewish founder mutations, we observed 9 deleterious BRCA mutations five or more times in ostensibly unrelated families and another 13 mutations in 3-4 families. We hypothesized that some of the rarer recurrent mutations observed in our population were due to different branches of the same family being tested independently without knowledge of previous testing of relatives. We examined 90 pedigrees for individuals with the same mutations that were seen three or more times for shared reported family medical history or surnames. Familial links were made in four instances out of a total of 22 shared mutations despite the fact that individuals were not aware that another family member had been tested. As more individuals undergo BRCA testing, we propose that this phenomenon will become more common. Being unaware of previous testing in a family not only affects the risk assessment but also likely increases the costs associated with the genetic testing and subsequent cancer screening in many cases.


Subject(s)
Family , Genes, BRCA1 , Genes, BRCA2 , Genetic Testing/economics , Mutation , Adult , Aged , Aged, 80 and over , Cost Savings , Ethnicity/genetics , Female , Heterozygote , Humans , Male , Middle Aged , Neoplasms/diagnosis , Neoplasms/economics , Neoplasms/genetics , Ohio , Pedigree , Retrospective Studies , Young Adult
4.
Clin Genet ; 71(1): 76-83, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17204050

ABSTRACT

Approximately one in three individuals will be affected by cancer in their lifetime in the United States, and some are at elevated risk because of family history. Although assessment of family history of cancer and cancer risk is the standard of care, the current health-care system appears unable to meet this need. Because individuals are increasingly using the Internet, web-based cancer risk assessment tools (CRATs) may provide a way to meet this need. The purpose of this review was to evaluate the types of familial CRATs available on the Internet and their nature. The current review evaluated five CRATs identified through an Internet search based on (i) their ability to identify those at the highest risk of cancer (i.e. those with hereditary cancer syndromes), (ii) their strengths and limitations based on criteria adapted from Rich and colleagues (2004, 2005), (iii) their readability based on four readability calculations, and (iv) their quality based on criteria from Health on the Net. The general limitations of CRATs as a whole were also delineated, including concerns about availability to those who are poor and underserved and those who have lower levels of literacy. Recommendations for future tools include assessing risk for a greater number of diseases, using theoretically driven approaches to increase the likelihood that individuals will engage in appropriate health behaviors, and making a greater effort to reach diverse populations.


Subject(s)
Genetic Predisposition to Disease , Internet , Neoplasms/genetics , Software , Evaluation Studies as Topic , Humans , Risk Assessment/methods
5.
Br J Cancer ; 92(10): 1922-6, 2005 May 23.
Article in English | MEDLINE | ID: mdl-15841079

ABSTRACT

Organ-specific differences in epidermal growth factor receptor (EGFR) mutational spectra and frequencies were found in lung cancer and sporadic and BRCA1/2-related breast cancers. Additionally, we found a high frequency of EGFR mutations in the tumour stroma of these invasive breast carcinomas. Those organ-specific mutational spectra and potential targets in the cancer-associated stroma might influence the efficacy of TKI therapy.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/genetics , Carcinoma/genetics , Enzyme Inhibitors/pharmacology , ErbB Receptors/genetics , Lung Neoplasms/genetics , Protein-Tyrosine Kinases/antagonists & inhibitors , Breast Neoplasms/pathology , Carcinoma/pathology , DNA Mutational Analysis , Genes, BRCA1 , Genes, BRCA2 , Humans , Lung Neoplasms/pathology , Stromal Cells
7.
J Med Genet ; 41(2): 81-91, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14757853

ABSTRACT

BACKGROUND: There have been many papers on the diagnostic criteria for specific hereditary cancer susceptibility syndromes and the likelihood that an individual has a germline mutation in one of the various cancer susceptibility genes. To assist health care professionals in deciding when a cancer genetics consultation is appropriate, available reports were critically reviewed in order to develop a single set of risk assessment criteria. METHODS: The criteria were based on a comprehensive review of publications describing diagnostic criteria for hereditary cancer syndromes and risk to first degree relatives of cancer patients. Priority was given to diagnostic criteria from consensus statements (for example, those from the National Comprehensive Cancer Network). Expert opinion from study personnel was then used to adopt a single set of criteria from other publications whenever guidelines differed. RESULTS: Based on family history, a set of criteria was developed to identify patients at risk for a hereditary cancer susceptibility syndrome, patients with moderate risk who might benefit from increased cancer surveillance, and patients who are at average risk. The criteria were applied to 4360 individuals who provided their cancer family history between July 1999 and April 2002, using a touch screen computer system in the lobby of a comprehensive cancer centre. They categorised an acceptable number of users into each risk level: 14.9% high risk, 13.7% moderate risk, and 59.6% average risk; 11.8% provided insufficient information for risk assessment. CONCLUSIONS: These criteria should improve ease of referral and promote consistency across centres when evaluating patients for referral to cancer genetics specialists.


Subject(s)
Genetic Counseling/statistics & numerical data , Genetic Predisposition to Disease/genetics , Neoplasms/genetics , Referral and Consultation/statistics & numerical data , Female , Genetic Predisposition to Disease/epidemiology , Humans , Male , Neoplasms/epidemiology , Risk Assessment
8.
Dev Biol ; 237(1): 173-82, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11518514

ABSTRACT

During Caenorhabditis elegans hermaphrodite development, the anchor cell induces the vulva and the uterine pi cells whose daughters connect to the vulva, thereby organizing the uterine-vulval connection. Both the initial selection of a single anchor cell during the anchor cell vs. ventral uterine precursor cell decision and the subsequent induction of the pi cell fate by the anchor cell are mediated by the lin-12 gene. Members of the presenilin gene family can cause early onset Alzheimer's disease when mutated and are also required for LIN-12/Notch signaling during development. We have shown that, in C. elegans, mutation of the sel-12-encoded presenilin results in pi cell induction defects. By contrast, other lin-12-mediated cell fate decisions occur normally in sel-12 mutants due to the redundant function of a second C. elegans presenilin called HOP-1. We found that the sel-12 egg-laying defect was partially rescued by expression of the sel-12 gene in the pi cells. sel-12-mediated pi cell fate specification provides a useful system for the analysis of presenilin function at single cell resolution.


Subject(s)
Caenorhabditis elegans Proteins , Caenorhabditis elegans/physiology , Helminth Proteins/physiology , Membrane Proteins/physiology , Uterus/embryology , Animals , Female , Helminth Proteins/chemistry , Helminth Proteins/genetics , Membrane Proteins/chemistry , Membrane Proteins/genetics , Mutation , Oviposition , Uterus/cytology
9.
Am J Med Genet ; 101(2): 91-9, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11391650

ABSTRACT

We have recently collected clinical information on 37 individuals with deletion of 22q13 and compared the features of these individuals with 24 previously reported cases. The features most frequently associated with this deletion are global developmental delay, generalized hypotonia, absent or severely delayed speech, and normal to advanced growth. Minor anomalies include dolicocephaly, abnormal ears, ptosis, dysplastic toenails, and relatively large hands. As with many terminal deletions involving pale G-band regions, the deletion can be extremely subtle and can go undetected on routine cytogenetic analysis. In fact, 32% of the individuals in our study had previous chromosome analyses that failed to detect the deletion. Eight of 37 individuals had deletion of 22q13 secondary to an unbalanced chromosome translocation. In the newborn, this deletion should be considered in cases of hypotonia for which other common causes have been excluded. In the older child, this syndrome should be suspected in individuals with normal growth, profound developmental delay, absent or delayed speech, and minor dysmorphic features. We recommend high-resolution chromosome analysis and fluorescence in situ hybridization studies, or molecular analysis to exclude this diagnosis.


Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 22/genetics , Abnormalities, Multiple/genetics , Abnormalities, Multiple/pathology , Adolescent , Adult , Child , Child, Preschool , Developmental Disabilities/genetics , Family Health , Female , Humans , Infant , Intellectual Disability/genetics , Karyotyping , Male , Syndrome , Translocation, Genetic
10.
Dermatol Surg ; 26(9): 874-6, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10971562

ABSTRACT

A pore of Winer is a common, benign epidermal appendageal tumor arising from a hair follicle. We present a case where routine removal of a pore of Winer revealed the presence of a trichoid basal cell carcinoma. We describe the history of these lesions, discuss clinical and histologic differential diagnoses, and propose an explanation for the presence of these tumor cells. No prior report of basal cell carcinoma within a pore of Winer has been documented in the literature.


Subject(s)
Carcinoma, Basal Cell/pathology , Hair Diseases/pathology , Hair Follicle/pathology , Nose Neoplasms/pathology , Aged , Carcinoma, Basal Cell/surgery , Diagnosis, Differential , Hair Diseases/surgery , Humans , Male , Mohs Surgery , Nose Neoplasms/surgery
13.
Lab Anim Sci ; 46(5): 497-502, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8905581

ABSTRACT

Tetracyclines have been used as in vivo indicators of new bone formation because they form complexes with mineral at bone-forming surfaces. Four of 12 dogs in a bone-labeling study developed clinical signs of renal disease (vomiting, diarrhea, dehydration, and azotemia) within 1 to 2 days of receiving oxytetracycline at a bone-labeling dose of 25 mg/kg of body weight, once daily for 2 consecutive days. To delineate the relationship between oxytetracycline administration and renal damage, six dogs were given the bone-labeling dose intravenously and were subsequently evaluated by determination of clinical signs, serum biochemical analysis, urinalysis, and histologic examination (experiment 1). Drug administration was modified in the five dogs remaining in the bone-labeling orthopedic study. These dogs received the oxytetracycline dose as a slow intravenous infusion diluted with 250 ml of lactated Ringer's solution (experiment 2). All six dogs of experiment 1 developed persistent isosthenuria within 2 days of receiving the bone-labeling dose of oxytetracycline. Clinical illness (three of six dogs) was associated with azotemia, creatinemia, and hyperphosphatemia. All dogs had multifocal, mild to moderate flattening of renal tubular epithelium, characteristic of nephrosis. None of the dogs of experiment 2 developed any clinical indications of renal disease, and the only biochemical abnormality was isosthenuria in two of the five dogs. Thus the development of clinical signs and biochemical abnormalities associated with the intravenous administration of oxytetracycline was obviated by the slow administration of a dilution of the calculated bone-labeling dose of the antibiotic.


Subject(s)
Anti-Bacterial Agents/toxicity , Bone and Bones/metabolism , Kidney Diseases/veterinary , Oxytetracycline/toxicity , Animals , Anti-Bacterial Agents/administration & dosage , Blood Urea Nitrogen , Creatinine/blood , Dogs , Injections, Intravenous , Kidney/drug effects , Kidney/pathology , Kidney Diseases/chemically induced , Kidney Tubules, Proximal/pathology , Male , Nephrosis/chemically induced , Nephrosis/pathology , Oxytetracycline/administration & dosage , Phosphorus/blood , Specific Gravity/drug effects
14.
Genomics ; 31(3): 359-66, 1996 Feb 01.
Article in English | MEDLINE | ID: mdl-8838318

ABSTRACT

G protein alpha subunits are encoded by a multigene family of 16 genes that can be grouped into four classes, Gq, Gs, Gi, and G12. The Gq class is composed of four genes in mouse and human, and two of these genes, Gna11 and Gna15, cosegregate on mouse chromosome 10. We have characterized the gene structures of murine Gna11 and Gna15. The two genes are tandemly duplicated in a head-to-tail array. The upstream gene, Gna11, is ubiquitously expressed, whereas expression of the downstream gene, Gna15, is restricted to hematopoietic cells. The coding sequence of each gene is contained within seven exons, and the two genes together span 43 kb, separated by 6 kb of intergenic region. We have found no evidence for alternative splicing within the coding sequence of either gene. Sequence alignments show that the positions of the six intervening sequences are conserved in the two genes, consistent with Gna11 and Gna15 arising by tandem duplication from a common progenitor gene in vertebrates. Phylogenetic trees reveal unequal evolutionary rates among alpha subunits of the Gq class. The rate of change is approximately six fold higher in Gna15 than in Gna11.


Subject(s)
GTP-Binding Proteins/genetics , Alternative Splicing , Animals , Base Sequence , DNA Primers , Exons , Introns , Mice , Mice, Inbred CBA , Molecular Sequence Data , Multigene Family , Phylogeny , Sequence Analysis
15.
Biochem Pharmacol ; 48(2): 391-401, 1994 Jul 19.
Article in English | MEDLINE | ID: mdl-7914406

ABSTRACT

A multidrug-resistant Chinese hamster cell line, LZ-8, was subcultured in increasing levels of doxorubicin (DOX) until capable of growth in 100 micrograms/mL DOX. This new derivative, designated LZ-100, is the most DOX-resistant line in the LZ series, based on a comparison of Ki-1 values from cell survival studies. This increased level of drug resistance in LZ-100 cells did not result from (i) higher levels of P-glycoprotein (P-gp) in the plasma membrane compared with LZ-8 cells, since this protein constitutes approximately 20% of the total plasma membrane protein in both cell lines, or (ii) more efficient drug pumping by the same amount of P-gp, since efflux of rhodamine 123 and DOX was comparable in the two cell lines. However, an altered drug distribution was observed in LZ-100 cells compared with wild-type V79 cells; in LZ-100 cells DOX was largely excluded from the nucleus and was sequestered in vesicles in the cytoplasm. The number of vesicles per cell seen after DOX exposure corresponded with the level of drug resistance achieved by the LZ cell lines studied. DOX concentration-response experiments revealed that vesicle formation exhibited a biphasic relationship, with an initial rapid increase followed by a plateau where no further increase was observed. Time-course studies in LZ-100 cells revealed that the maximum number of DOX-containing vesicles per cell occurred 3-4 hr following initiation of DOX treatment. Radiation exposure (10 Gy) immediately preceding DOX treatment decreased the number of vesicles formed in LZ-100 cells by more than one-half and altered the subcellular distribution of DOX from an almost exclusively cytoplasmic to a homogeneous nuclear/cytoplasmic distribution. This redistribution was not a result of radiation inhibition of P-gp efflux. The inhibitory effect of radiation on vesicle formation increased with increasing radiation dose up to 10 Gy. Drug-containing vesicles were also observed in LZ-100 cells following exposure to mitoxantrone or daunorubicin (to which LZ-100 cells are also resistant), but fewer vesicles were observed than with DOX. These studies demonstrate that the drug sequestration phenomenon (i) occurs in cells exhibiting widely different levels of drug resistance, (ii) correlates with the level of drug resistance in LZ cell lines, (iii) occurs rapidly following exposure to DOX, mitoxantrone, or daunorubicin, and (iv) can be inhibited by irradiation.(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Doxorubicin/pharmacology , Drug Resistance , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Animals , Carrier Proteins/metabolism , Cell Line , Cell Survival/drug effects , Cricetinae , Cricetulus , Daunorubicin/pharmacology , Membrane Glycoproteins/metabolism , Mitoxantrone/pharmacology
16.
Biochem Pharmacol ; 44(9): 1869-77, 1992 Nov 03.
Article in English | MEDLINE | ID: mdl-1360214

ABSTRACT

Multidrug-resistant LZ-8 cells are 9000-fold more resistant to Adriamycin (ADRM) exposure than wild-type V79 cells. To understand more about the mechanisms producing such high level resistance, we tested whether LZ-8 cells inactivate ADRM toxicity to a greater extent than wild-type V79 cells. ADRM was recovered from (1) culture media of wild-type V79 and ADRM-resistant LZ-8 cells; (2) V79 and LZ-8 cells; and (3) LZ-8 cell plasma membrane, and the cytotoxicity was determined by treating V79 cells for 1 hr with a known concentration of the recovered ADRM. ADRM obtained from LZ-8 cells or its culture medium exhibited less cytotoxicity than that recovered from V79 cells or its culture medium. ADRM extracted from LZ-8 cell plasma membrane was noncytotoxic. HPLC analysis revealed that the extracted ADRM was structurally changed compared to stock ADRM. The retention time in the column was 7 min for stock ADRM, and 23 min for the recovered ADRM. Thus, LZ-8 cells have an increased ability to transform ADRM into a noncytotoxic form compared to wild-type V79 cells. This transformation involves structural conversion into a previously unidentified ADRM metabolite. The greatly increased survival of LZ-8 cells compared to V79 cells after ADRM treatment is due to at least two mechanisms: (1) an enhanced ability to inactivate the cytotoxicity of ADRM, and (2) increased drug efflux resulting from the amplification and overexpression of the pgp 1 gene in these cells. Our results suggest the possibility that P-glycoprotein participates in drug binding/inactivation in addition to serving as a drug efflux pump.


Subject(s)
Doxorubicin/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Animals , Cell Line , Cell Membrane , Chromatography, High Pressure Liquid , Cricetinae , Cricetulus , Culture Media , Doxorubicin/metabolism , Doxorubicin/toxicity , Drug Resistance/physiology , Inactivation, Metabolic , Intracellular Fluid/metabolism , Membrane Glycoproteins/metabolism , Protein Binding , Stem Cells/drug effects
17.
Radiat Res ; 132(1): 105-11, 1992 Oct.
Article in English | MEDLINE | ID: mdl-1410265

ABSTRACT

A comparative study of the radiation and/or doxorubicin (DOX) survival response for synchronous populations of Chinese hamster V79 cells and two DOX-resistant variants (77A and LZ-8) was performed. The greatest cellular radiation sensitivity was observed in mitosis, while the greatest resistance was observed during late S phase for the three cell lines. The variation in radiation response throughout the cell cycle was expressed as a change in the width of the shoulder of the survival curves (Dq) with little change in D0. This suggests that each phase of the cell cycle has a different capacity for accumulation of radiation injury. The radiation age-response function for the three cell lines revealed that 77A and LZ-8 cells were more radiosensitive than V79 cells throughout the cell cycle. Exposure of synchronous populations to DOX (1.84 microM for V79, 9.21 microM for 77A, and 921 microM for LZ-8) for 1 h as a function of cell cycle phase revealed that V79, 77A, and LZ-8 cells exhibited the greatest sensitivity to DOX in mitosis and the most resistance to DOX during S phase, as indicated by the differences in the slope of the initial component of the survival curve. Levels of P-glyco-protein (P-gp) are probably not a factor contributing to DOX age-response function since P-gp levels remain constant throughout the cell cycle in all three cell lines. Synchronous populations of V79, 77A, and LZ-8 cells sequentially treated with DOX and radiation at various cell cycle phases were also analyzed. The results showed that the interaction between radiation and DOX damage resulted in a reduced cellular capacity for the accumulation of radiation damage throughout the cell cycle, as indicated by a decrease in the width of the shoulder of the survival curve. Overall, both DOX-sensitive V79 cells and DOX-resistant 77A and LZ-8 cells exhibited (1) a similar age-response function for radiation or DOX, and (2) no differences in the effects of DOX on radiation-induced damage throughout the cell cycle. These results indicate that acquired resistance to DOX associated with increased levels of P-gp in the cell membrane did not appear to affect the age-response function for radiation or DOX, and the nature of the interaction between damage caused by radiation and DOX was also not affected.


Subject(s)
Cell Survival/drug effects , Cell Survival/radiation effects , Doxorubicin/pharmacology , Radiation Tolerance/physiology , Animals , Cell Cycle/physiology , Cell Line , Cricetinae , Drug Tolerance/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...